News
Waters and Sartorius Partner to Help Bioprocess Scientists Accelerate Clone Selection and Process Development
Waters Corporation (NYSE: WAT) and Sartorius (DAX: SRT:GR) announced today they will partner to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine in Children 5 to <12 Years
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted
New Poll Reveals Significant Changes to Seniors’ Lives and Values Since Onset of COVID-19 Pandemic
Findings released today from a new Humana Inc. (NYSE: HUM) national poll indicate the extent to which seniors’ health – and their values related to health – have been affected since the onset of
Humana Expands Footprint in Maryland
Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding its footprint in Maryland and, for the first time, offering affordable Humana Medicare Advantage plans to beneficiaries
Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with
IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the
Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults
Pfizer Inc. (NYSE:PFE) announced today that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend PREVNAR 20™ (Pneumococcal
Waters and University of Delaware Announce Bioprocessing Innovation Partnership, Plan 2022 Opening of Immerse Delaware Lab
Waters Corporation (NYSE:WAT) and the University of Delaware today announced a five-year research partnership to develop new analytical solutions for bioprocessing and biomanufacturing. Key to this
Humana Expands Footprint, Health Plan Choices in New Jersey
Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding health plan choices for Medicare beneficiaries in New Jersey by once again adding counties in which its 2022 Humana
Humana Healthy Horizons in Kentucky Announces $207,000 Investment to Reduce “Digital Divide” and Improve Access to Health Care in Lyon County, KY
Humana Healthy Horizons in Kentucky, Humana’s (NYSE: HUM) Kentucky Medicaid Plan, is pleased to announce a $207,000 investment that will upgrade infrastructure in Lyon County, KY in order to
For First Time, Humana Offering Medicare Advantage Plans in Connecticut
Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding health plan choices for Medicare beneficiaries in Connecticut by offering affordable Humana Medicare Advantage plans in
Pfizer’s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the 100 mg and
Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer
Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of
Humana Continues Extensive Statewide Expansion in Tennessee
Leading health and well-being company Humana Inc. (NYSE: HUM) today announced another major expansion of its Medicare Advantage (MA) offerings across Tennessee for the 2022 plan year. It’s part of
Humana Expands Access to Affordable Medicare Options in Eastern North Carolina
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today it is introducing a new affordable, whole person health care Medicare Advantage PPO plan in rural communities located
PerkinElmer Receives FDA Emergency Use Authorization for Respiratory SARS-CoV-2 Panel
PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1
Humana Foundation Donates $200,000 to Recovery Efforts for Louisianans Impacted by Hurricane Ida
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, is donating $200,000 to the recovery and relocation efforts for those impacted by Hurricane Ida in
Waters Corporation Appoints John M. Ballbach to Board of Directors
Waters Corporation (NYSE:WAT) today announced the appointment of John M. Ballbach to its Board of Directors, effective October 5, 2021. Mr. Ballbach currently serves on the Board of RPM
Louisville Nonprofits Awarded $1.8 Million Through the Humana Foundation’s Community Partners Program
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, is awarding $1.8 million to several nonprofit organizations in Louisville as part of its ongoing Community
Humana Expanding Medicare Advantage Health Plans in 2022 to Address Beneficiaries’ Most Important Needs, Delivering Predictable, Affordable and Understandable Health Care
Humana Inc. (NYSE: HUM) today announced details of its 2022 Medicare product offerings, including many Medicare Advantage and Prescription Drug Plans that are built to address the needs of diverse
Japan’s MHLW Approves Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor
Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released
Pfizer Inc. (NYSE:PFE) today announced positive top-line results from a Phase 3 study (B7471004) evaluating the safety and immunogenicity of PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine)
The University of Mississippi Medical Center and Humana Sign Agreement, Expanding Humana’s Medicare Advantage Provider Network in Jackson, Lexington and Grenada
The University of Mississippi Medical Center (UMMC), Mississippi’s only academic health science center, and Humana, a leading health and well-being company, have signed an in-network agreement
Agilent Announces Thought Leader Award to Bernhard Lendl at the TU Wien (Vienna)
Agilent Technologies Inc. (NYSE: A) today announced Professor Bernhard Lendl has been selected to receive a prestigious Agilent Thought Leader Award. Highly renowned in the field of vibrational